Today, the German government presented a revised cornerstone paper for the planned cannabis legalization. According to that, cannabis will be allowed to be cultivated in certain quantities privately and in Cannabis Social Clubs, in a second step there will also be regional pilot projects. Finn Hänsel, CEO of Berlin-based cannabis company Sanity Group, comments on this in a first statement.

Berlin/Vancouver, January 16, 2023 – Endosane Pharmaceuticals, a Berlin-based pharmaceutical company, and PreveCeutical Medical Inc. (CSE: PREV, OTCQB: PRVCF, FSE: 18H) of Canada have entered into a licensing agreement through which Endosane Pharmaceuticals has obtained exclusive access and use rights to the Sol-Gel technology developed by PreveCeutical Medical for the delivery of cannabinoid products.

Today, the official cornerstone paper of the German government on the controlled dispensing of cannabis to adults for consumption purposes was presented. This follows details released from an internal, non-coordinated draft that became public last week. From the point of view of Sanity Group, one of the leading cannabis companies in Germany, the final and revised version contains interesting approaches and some fruitful frameworks, but the Berlin-based company is critical of certain points.

Leading German cannabis company Sanity Group announced today a $37.6M Series B financing round – Europe’s largest cannabis investment round to date. The funding round was led by BAT Group* with ongoing commitment from existing Sanity Group investors such as Redalpine and Casa Verde Capital and brings total funds raised by the company to over $100M.